Inhibrx, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
11025 N. Torrey Pines Road, Suite 200, La Jolla, CA
State of incorporation
CA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 582 % -25.6%
Debt-to-equity 640 % -75.6%
Return On Equity -1.26K % -742%
Return On Assets -91.7 % -27.1%
Operating Margin -14K % -24.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52.4M shares +20.1%
Common Stock, Shares, Outstanding 49.2M shares +12.9%
Entity Public Float 893M USD +170%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 54.6M shares +25.2%
Weighted Average Number of Shares Outstanding, Diluted 54.6M shares +25.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.78M USD +39.3%
Research and Development Expense 218M USD +77.8%
General and Administrative Expense 33M USD +46.7%
Operating Income (Loss) -249M USD -73.3%
Nonoperating Income (Expense) -20.2M USD -6.41%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -78.7M USD -60.9%
Income Tax Expense (Benefit) 3K USD 0%
Net Income (Loss) Attributable to Parent -271M USD -66.5%
Earnings Per Share, Basic -5.44 USD/shares -38.1%
Earnings Per Share, Diluted -5.44 USD/shares -38.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 252M USD +7.78%
Accounts Receivable, after Allowance for Credit Loss, Current 171K USD -43.8%
Other Assets, Current 539K USD +152%
Assets, Current 275M USD +12.6%
Property, Plant and Equipment, Net 6.97M USD +180%
Operating Lease, Right-of-Use Asset 2.49M USD -42%
Other Assets, Noncurrent 4.59M USD +44.9%
Assets 289M USD +13.7%
Accounts Payable, Current 14.8M USD +35.5%
Employee-related Liabilities, Current 2.1M USD +19.8%
Accrued Liabilities, Current 51.3M USD +161%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 71.9M USD +120%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 561K USD -79.1%
Liabilities 277M USD +16.1%
Retained Earnings (Accumulated Deficit) -692M USD -64.4%
Stockholders' Equity Attributable to Parent 11.6M USD -23.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -35.1M USD -224%
Liabilities and Equity 289M USD +13.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -63.1M USD -57.8%
Net Cash Provided by (Used in) Financing Activities 38.7M USD +10779%
Net Cash Provided by (Used in) Investing Activities -1.12M USD -4765%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 49.2M shares +12.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -25.4M USD +35.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 252M USD +7.78%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6.28M USD +318%
Deferred Tax Assets, Valuation Allowance 146M USD +59.4%
Deferred Tax Assets, Gross 147M USD +57.8%
Operating Lease, Liability 2.68M USD -41.6%
Payments to Acquire Property, Plant, and Equipment 1.12M USD +4765%
Lessee, Operating Lease, Liability, to be Paid 2.83M USD -43.9%
Property, Plant and Equipment, Gross 14M USD +68.7%
Operating Lease, Liability, Current 2.12M USD +10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.14M USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.14M USD -49.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 149K USD -67.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.14M USD -49.4%
Deferred Tax Assets, Operating Loss Carryforwards 68.3M USD +28.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Unrecognized Tax Benefits 4.65M USD +29.3%
Operating Lease, Payments 401K USD +11.4%
Additional Paid in Capital 704M USD +61.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.26M USD +3.55%
Deferred Tax Assets, Net of Valuation Allowance 658K USD -51.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%